IN8bio

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bios platform employs allogeneic, autologous, and genetically modified approaches to develop novel...

Cell therapy,solid tumors,glioblastoma,drug resistant immunotherapy,gamma delta t cells,hematological tumors,allogeneic,autologous,ipsc,genetically modified gamma delta t cells,and gbm

In8bio operates in the Biotechnology research industry.

In8bio's revenue is 11m - 100m

In8bio has 11 - 50 employees.